482 related articles for article (PubMed ID: 18952456)
1. Management of complications of androgen deprivation therapy in the older man.
Mohile SG; Mustian K; Bylow K; Hall W; Dale W
Crit Rev Oncol Hematol; 2009 Jun; 70(3):235-55. PubMed ID: 18952456
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
3. Managing complications of androgen deprivation therapy for prostate cancer.
Holzbeierlein JM
Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
5. Complications of androgen deprivation therapy: prevention and treatment.
Holzbeierlein JM; Castle E; Thrasher JB
Oncology (Williston Park); 2004 Mar; 18(3):303-9; discussion 310, 315, 319-21. PubMed ID: 15065701
[TBL] [Abstract][Full Text] [Related]
6. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
8. Complications of androgen-deprivation therapy for prostate cancer.
Holzbeierlein JM; Castle EP; Thrasher JB
Clin Prostate Cancer; 2003 Dec; 2(3):147-52. PubMed ID: 15040857
[TBL] [Abstract][Full Text] [Related]
9. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy complications.
Allan CA; Collins VR; Frydenberg M; McLachlan RI; Matthiesson KL
Endocr Relat Cancer; 2014 Aug; 21(4):T119-29. PubMed ID: 24872511
[TBL] [Abstract][Full Text] [Related]
11. Acupuncture for hot flashes in men treated with androgen deprivation therapy.
Hirsch LM; Goldstein LE
Can J Urol; 2015 Aug; 22(4):7938-41. PubMed ID: 26267037
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for prostate cancer.
Sharifi N; Gulley JL; Dahut WL
JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
[TBL] [Abstract][Full Text] [Related]
13. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms.
Grunfeld EA; Halliday A; Martin P; Drudge-Coates L
Cancer Nurs; 2012; 35(1):63-9. PubMed ID: 21558849
[TBL] [Abstract][Full Text] [Related]
14. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
18. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
Patil T; Bernard B
Oncology (Williston Park); 2018 Sep; 32(9):470-4, CV3. PubMed ID: 30248169
[TBL] [Abstract][Full Text] [Related]
19. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
